NCT02608853View on ClinicalTrials.gov

Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants

CompletedOBSERVATIONAL
Enrollment

9,999

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
OTHER

No treatment given

No treatment is actively administered. Patients are treated according to routine clinical practice at the discretion of their treating physicians.

Trial Locations (1)

08540

Novo Nordisk Clinical Trial Call Center, Princeton

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY